Abstract
We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.
| Original language | English |
|---|---|
| Pages (from-to) | 119-124 |
| Number of pages | 6 |
| Journal | Japanese Journal of Chemotherapy |
| Volume | 58 |
| Issue number | 2 |
| Publication status | Published - 2010 Mar |
| Externally published | Yes |
Fingerprint
Keywords
- Arbekacin
- Questionnaire
- Teicoplanin
- Therapeutic drug monitoring
- Vancomycin
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Therapeutic drug monitoring survey of anti-MRSA agents in Japan. / Kobayashi, Masahiro; Takesue, Yoshio; Tanigawara, Yusuke; Mikamo, Hiroshige; Kimura, Toshimi; Hirata, Sumio; Shiraishi, Tadashi; Sakaeda, Toshiyuki; Takakura, Shunji.
In: Japanese Journal of Chemotherapy, Vol. 58, No. 2, 03.2010, p. 119-124.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Therapeutic drug monitoring survey of anti-MRSA agents in Japan
AU - Kobayashi, Masahiro
AU - Takesue, Yoshio
AU - Tanigawara, Yusuke
AU - Mikamo, Hiroshige
AU - Kimura, Toshimi
AU - Hirata, Sumio
AU - Shiraishi, Tadashi
AU - Sakaeda, Toshiyuki
AU - Takakura, Shunji
PY - 2010/3
Y1 - 2010/3
N2 - We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.
AB - We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.
KW - Arbekacin
KW - Questionnaire
KW - Teicoplanin
KW - Therapeutic drug monitoring
KW - Vancomycin
UR - http://www.scopus.com/inward/record.url?scp=77950801821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950801821&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:77950801821
VL - 58
SP - 119
EP - 124
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - 2
ER -